PROLOR Biotech to Present at the UBS 2009 Global Life Sciences ...(an amino acid sequence that occurs natur...)

Date:9/16/2009

an amino acid sequence that occurs naturally in humans, the carboxyl terminal peptide. When attached to a therapeutic protein, CTP extends the time that the protein is active in the body. The potential utility of the technology has been demonstrated by Schering-Plough, which in 2009 announced successful data from its Phase III ENGAGE trial demonstrating that women receiving a single injection of the fertility drug FSH-CTP achieved the same pregnancy rates as women receiving seven consecutive daily injections of commercial FSH. This 1,509 patient trial formed the basis for a Marketing Authorization Application by Schering-Plough that is currently under review by the European Medicines Agency. PROLOR is using the same CTP technology to extend the duration of action of human growth hormone and other therapeutic proteins. It has an exclusive license to the CTP technology from Washington University in St. Louis for use with all therapeutic proteins except for the four fertility hormones licensed to Schering-Plough.

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, proprietary versions of already-approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on PROLOR, visit www.prolor-biotech.com.

Safe Harbor Statement: This press release contains forward-looking statements, including statemen
'/>"/>

SOURCE PROLOR Biotech, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
2. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
3. PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
4. Strong Social Connections Needed for Biotech to Grow in Los Angeles
5. Micromet to Present at the 16th Annual NewsMakers in the Biotech Industry Conference on September 16, 2009
6. Ganeden Biotech Introduces the First Probiotic Thin Strip
7. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
8. China Agro-Technology Holdings Announces Launch of Agricultural Biotech Website
9. BioSpecifics Technologies Corp. To Present at BioCentury NewsMakers in the Biotech Industry Conference
10. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
11. Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer